Is Merck Stock (MRK) Halal? A Complete Analysis

The Short Answer

Merck stock (MRK) is still considered halal in ZakatInvest's qualitative catalog, but fails the current filing-based asset screen. Merck's pharmaceutical and vaccine activity is generally permissible, but its March 31, 2026 filing shows debt/assets of 38.16%, above the examined 33% limits. Product, licensing and customer allocation remain qualitative questions.

Pharmaceutical and vaccine development, manufacture, and distribution is generally permissible at the activity level. The current quantitative screen fails on debt/assets; the page keeps medicine formulations, animal-health products and customer allocation as qualitative concerns.

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

Merck's Business Activity

Merck is organized into two reporting segments:

• Pharmaceutical: Prescription human-health medicines and vaccines, including:
  • Oncology: Keytruda (pembrolizumab) — an anti-PD-1 immune checkpoint inhibitor that is the largest-selling oncology drug globally, used across numerous tumor types; plus other oncology medicines
  • Vaccines: Gardasil and Gardasil 9 for HPV, Pneumovax and Vaxneuvance for pneumococcal disease, ProQuad/M-M-R II for measles-mumps-rubella, RotaTeq for rotavirus, and the Ervebo Ebola vaccine
  • Cardiovascular and Diabetes: Januvia and Janumet (sitagliptin) for type-2 diabetes, plus other cardiometabolic medicines
  • HIV: Isentress and the Delstrigo and Pifeltro single-tablet regimens
  • Hospital and Specialty Care: Bridion (sugammadex) and other hospital-administered medicines
  • Other primary-care medicines
• Animal Health: Livestock and companion-animal pharmaceuticals, vaccines, parasiticides, and animal-identification products through Merck Animal Health — one of the global leaders in the animal-health category

All segments are unambiguously permissible at the activity level under standard Sharia methodology.

Concerns to Be Aware Of

1. Porcine-Derived Materials in Some Vaccines

Some vaccines and pharmaceutical products may contain trace porcine-derived or other animal-derived materials in manufacturing or formulation. Scholars generally classify medicines as permissible under necessity (darura) even where alternative formulations are unavailable — the prohibition on porcine materials in food does not extend to life-saving medicines where no halal alternative exists. This is a consumer-product consideration rather than a corporate-Sharia screening concern.

2. Animal-Health Reproductive-Management Products

Merck Animal Health includes some reproductive-management product categories where individual investors may wish to apply additional scrutiny. These are a small share of total revenue and the broader animal-health business — vaccines, parasiticides, anti-infectives — is unambiguously permissible.

3. Minor Interest Income

Merck holds substantial cash and short-term investment balances that generate small interest income. This is well below the 5% Sharia threshold but warrants purification of a small portion of dividends.

4. Keytruda Patent-Cliff Considerations

Keytruda faces loss of exclusivity beginning around 2028. This is a business-quality and revenue-concentration consideration rather than a Sharia screen concern. Merck has been investing heavily in pipeline diversification to offset future Keytruda revenue erosion.

Financial Ratios (March 31, 2026)

Based on Merck's most recent financial statements:

• Interest-bearing debt / assets: 38.16% — above the examined 33% asset limits ❌
• Cash + securities / assets: 4.51% ✅
• Receivables + cash / assets: 13.63% ✅
• Interest income / revenue: 0.21% ✅; prohibited-revenue allocation remains incomplete

How to Read This Result

This page does not infer current index membership or attribute a verdict to third-party screening apps. The documented filing-based result is a debt-ratio failure under the examined asset methodologies; investors following a different methodology should obtain a qualified scholar's view.

Bottom Line

Merck & Co. (MRK) has a FAIL result under the current filing-based asset screen because debt/assets is 38.16%. The healthcare activity is generally permissible and disclosed interest income is low, but the quantitative failure and product/customer questions should be resolved before treating the security as Sharia-compliant.

Pharmaceutical peers require company-specific evidence rather than a shared sector label. AbbVie's March 2026 total-assets screen fails because its debt ratio is above the examined limits, while its medicines and product-level questions remain part of a separate qualitative review.